We have observed
6 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 13, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
BOMBESIN RECEPTOR TARGETING PEPTIDE INCORPORATING A 1, 2, 3-TRIAZOLE GROUP IN THE BACKBONE FOR PREPARING IN VIVO DIAGNOSTIC AND THERAPEUTIC AGENTS
SELF-ASSEMBLING PEPTIDE NANOPARTICLES AS VACCINES AGAINST INFECTION WITH NOROVIRUS
ALLERGENS FROM INSECTS
ANTIBODIES AGAINST TROPOMYOSIN-RELATED KINASE B RECEPTORS
DESIGNED REPEAT PROTEINS BINDING TO SERUM ALBUMIN
Composition for treatment of pathogens that are resistant to tetracyclines